JP2018536706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536706A5 JP2018536706A5 JP2018541599A JP2018541599A JP2018536706A5 JP 2018536706 A5 JP2018536706 A5 JP 2018536706A5 JP 2018541599 A JP2018541599 A JP 2018541599A JP 2018541599 A JP2018541599 A JP 2018541599A JP 2018536706 A5 JP2018536706 A5 JP 2018536706A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cheh
- aebs
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 20
- FXNSVEQMUYPYJS-UHFFFAOYSA-N 4-(2-aminoethyl)benzenesulfonamide Chemical compound NCCC1=CC=C(S(N)(=O)=O)C=C1 FXNSVEQMUYPYJS-UHFFFAOYSA-N 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 6
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 6
- 229950011318 cannabidiol Drugs 0.000 claims 6
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 6
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 6
- 102000015694 estrogen receptors Human genes 0.000 claims 5
- 108010038795 estrogen receptors Proteins 0.000 claims 5
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 5
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 5
- 229940124639 Selective inhibitor Drugs 0.000 claims 4
- 229940114079 arachidonic acid Drugs 0.000 claims 4
- 235000021342 arachidonic acid Nutrition 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 claims 4
- 229940011871 estrogen Drugs 0.000 claims 4
- 239000000262 estrogen Substances 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 206010000830 Acute leukaemia Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010005949 Bone cancer Diseases 0.000 claims 3
- 208000018084 Bone neoplasm Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 3
- 206010027406 Mesothelioma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims 3
- 206010034299 Penile cancer Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 208000024519 eye neoplasm Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000002313 intestinal cancer Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000010453 lymph node cancer Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 201000008106 ocular cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 239000011885 synergistic combination Substances 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 2
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- GZFYZYBWLCYBMI-MYZJJQSMSA-N 3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride Chemical compound Cl.C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCN(CC)CC)C1 GZFYZYBWLCYBMI-MYZJJQSMSA-N 0.000 claims 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 2
- YIKKMWSQVKJCOP-ABXCMAEBSA-N 7-ketocholesterol Chemical compound C1C[C@H](O)CC2=CC(=O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]3[C@]21C YIKKMWSQVKJCOP-ABXCMAEBSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims 2
- 229930192627 Naphthoquinone Natural products 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 150000002791 naphthoquinones Chemical class 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 201000011096 spinal cancer Diseases 0.000 claims 2
- 208000014618 spinal cord cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 2
- 229960002722 terbinafine Drugs 0.000 claims 2
- SYHDSBBKRLVLFF-UHFFFAOYSA-N triparanol Chemical group C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC(C)=CC=1)CC1=CC=C(Cl)C=C1 SYHDSBBKRLVLFF-UHFFFAOYSA-N 0.000 claims 2
- 229950005498 triparanol Drugs 0.000 claims 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- NFIXBCVWIPOYCD-UHFFFAOYSA-N N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 108010021637 cholesterol-5 alpha,6 alpha-epoxide hydrase Proteins 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical group C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 1
- 229960003608 clomifene Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 210000000607 neurosecretory system Anatomy 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229950007967 tesmilifene Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 235000012711 vitamin K3 Nutrition 0.000 claims 1
- 239000011652 vitamin K3 Substances 0.000 claims 1
- 229940041603 vitamin k 3 Drugs 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246780P | 2015-10-27 | 2015-10-27 | |
| US62/246,780 | 2015-10-27 | ||
| PCT/IL2016/051166 WO2017072773A1 (en) | 2015-10-27 | 2016-10-27 | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536706A JP2018536706A (ja) | 2018-12-13 |
| JP2018536706A5 true JP2018536706A5 (cg-RX-API-DMAC7.html) | 2019-12-05 |
| JP7078538B2 JP7078538B2 (ja) | 2022-05-31 |
Family
ID=57406292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541599A Active JP7078538B2 (ja) | 2015-10-27 | 2016-10-27 | がんの治療のためのカンナビジオール及び第二の治療剤を含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11090275B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3368024B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7078538B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180102053A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109310648B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016347662B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018008601A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3002767C (cg-RX-API-DMAC7.html) |
| IL (1) | IL258854B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017072773A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020161083A1 (en) * | 2019-02-04 | 2020-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating blood-brain barrier |
| EP3993780A4 (en) * | 2019-07-02 | 2023-07-26 | Portland Technology Holdings LLC | HEMP EXTRACT FOR THE TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS |
| CA3109520C (en) * | 2019-07-21 | 2021-09-07 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| EP4132486A4 (en) * | 2020-04-09 | 2024-04-03 | Laviolette, Steven Robert | Combination of cannabidiol and a ppar agonist |
| CN111773390B (zh) * | 2020-07-01 | 2021-08-20 | 南京大学 | 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用 |
| CN113368085A (zh) * | 2021-06-05 | 2021-09-10 | 昆明医科大学第一附属医院 | 大麻二酚在调节肿瘤微生态治疗乳腺癌药物研制中的应用 |
| CN113384563A (zh) * | 2021-06-16 | 2021-09-14 | 冯敏 | 大麻二酚在制备治疗非霍奇金淋巴瘤的药物中的应用 |
| KR20240116463A (ko) | 2021-10-26 | 2024-07-29 | 더 유니버시티 오브 뉴캐슬 | 대마 추출물을 이용한 자궁내막증 및 기타 비암성 부인과 장애의 치료 방법 |
| WO2023076931A2 (en) | 2021-10-26 | 2023-05-04 | Ecofibre Limited | Systems and methods for producing hemp extracts and compositions |
| IL312273A (en) | 2021-10-26 | 2024-06-01 | Ecofibre Usa Inc | Methods for treating endometrial cancer using hemp extract |
| US12440454B2 (en) | 2022-02-01 | 2025-10-14 | Portland Technology Holdings Llc | Pharmaceutical compositions containing hemp extract for administration to felines and related methods |
| WO2024003373A1 (en) * | 2022-06-30 | 2024-01-04 | Univerza V Mariboru | Cannabinoid compositions against cancer, their identification and personalization of cannabis-based cancer therapy |
| US20240009211A1 (en) * | 2022-07-05 | 2024-01-11 | Neocannbio Co., Ltd. | Pharmaceutical composition for treatment of lung cancer comprising cannabidiol and anticancer agent as active ingredients, and use thereof |
| KR20240036953A (ko) * | 2022-09-14 | 2024-03-21 | 주식회사 네오켄바이오 | 칸나비디올 및 항암제를 유효성분으로 포함하는 간암 치료용 약학 조성물 및 이의 용도 |
| WO2024091987A1 (en) | 2022-10-26 | 2024-05-02 | Ecofibre USA Inc. | Methods of treating estrogen sensitive diseases with cannabis extract |
| WO2024091989A1 (en) | 2022-10-26 | 2024-05-02 | Ecofibre USA Inc. | Stabilized compositions comprising cannabidiol |
| WO2024097631A2 (en) * | 2022-11-02 | 2024-05-10 | Morehouse School Of Medicine | Methods of treating pain and drepression |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| AU664978B2 (en) * | 1990-12-17 | 1995-12-14 | University Of Manitoba | Improved treatment method for cancer |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US6380253B1 (en) * | 2000-01-05 | 2002-04-30 | Efa Sciences Llc | Method of stabilizing and potentiating the action of anti-angiogenic substances |
| US20020040011A1 (en) * | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
| US8449908B2 (en) * | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| US9084771B2 (en) * | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
| GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2475183B (en) | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
| FR2947340B1 (fr) * | 2009-06-25 | 2011-08-12 | Affichem | Detection de l'etat oncogene de cellules humaines ou de mammiferes par presence d'un marqueur et evaluation de l'activite d'un medicament par dosage dudit marqueur |
| GB201117956D0 (en) | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
| GB2515312A (en) | 2013-06-19 | 2014-12-24 | Gw Pharma Ltd | The use of phytocannabinoids in the treatment of ovarian carcinoma |
| GB2527590A (en) * | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
-
2016
- 2016-10-27 BR BR112018008601A patent/BR112018008601A2/pt not_active Application Discontinuation
- 2016-10-27 WO PCT/IL2016/051166 patent/WO2017072773A1/en not_active Ceased
- 2016-10-27 IL IL258854A patent/IL258854B2/en unknown
- 2016-10-27 CN CN201680062738.8A patent/CN109310648B/zh active Active
- 2016-10-27 JP JP2018541599A patent/JP7078538B2/ja active Active
- 2016-10-27 CA CA3002767A patent/CA3002767C/en active Active
- 2016-10-27 US US15/771,816 patent/US11090275B2/en active Active
- 2016-10-27 AU AU2016347662A patent/AU2016347662B2/en active Active
- 2016-10-27 CA CA3187317A patent/CA3187317A1/en active Pending
- 2016-10-27 KR KR1020187014034A patent/KR20180102053A/ko not_active Ceased
- 2016-10-27 EP EP16801851.3A patent/EP3368024B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536706A5 (cg-RX-API-DMAC7.html) | ||
| CN109310648B (zh) | 用于治疗癌症的包含大麻二酚和第二治疗剂的组合物 | |
| IL290789A (en) | Methods for the treatment of breast cancer with a history of tetrahydronaphthalene as estrogen receptor antagonists | |
| BR132020025325E2 (pt) | posicionamento de banda ultralarga para comunicação e rastreamento por ultrassom sem fio | |
| SA521430055B1 (ar) | عمليات ومركبات لتحضير مدهور مستقبل إستروجين انتقائي | |
| JP2018514593A5 (cg-RX-API-DMAC7.html) | ||
| RU2021107754A (ru) | ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА | |
| MX342330B (es) | Formulaciones de 4-amino-2-(2, 6-dioxopiperidin-3-il) isoindolin-1, 3-diona. | |
| DK1272505T3 (da) | 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater | |
| BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
| Hwang et al. | Human papillomavirus-related carcinoma with adenoid cystic-like features of the inferior turbinate: a case report | |
| EP3520708A3 (en) | Systems and tools for connecting to tissue | |
| HRP20211652T1 (hr) | Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze | |
| WO2019244159A8 (en) | Delaying pre-term birth | |
| Valera et al. | From the Women’s Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition | |
| AR039282A1 (es) | Moduladores de receptores de estrogeno | |
| TN2010000007A1 (en) | 8-beta- substituted estratrienes as selectively active estrogens | |
| PH12021551437A1 (en) | Estrogen receptor antagonist | |
| BRPI0822415B8 (pt) | conjugado de hidroxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição tendo efeito de matar célula de tumor, e, método para produzir o conjugado de hidroxipolímero modificado | |
| Hoefgen | Ethinylestradiol/norethisterone | |
| Kashiyama | Low-grade endometrial stromal sarcoma: case report | |
| Powles et al. | Endocrine prevention of breast cancer | |
| HRP20210384T1 (hr) | 2,2-difluorpropionamidni derivat bardoksolon-metila, farmaceutski njegovi pripravci i polimorfi, namijenjeni upotrebi u liječenju određenih stanja | |
| HK40119356A (zh) | 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法 | |
| Mohammad et al. | Multicentric myxoid liposarcoma; a case report and literature review |